Trevi Therapeutics provides additional analysis of Haduvio in chronic cough

Trevi Therapeutics (TRVI) announced additional analyses from the Phase 2a RIVER trial of Haduvio for the treatment of patients with refractory chronic cough, or RCC. In March 2025, the company announced positive topline results, where Haduvio met the primary endpoint with a statistically-significant reduction in the objective 24-hour cough frequency of 67% from baseline and 57% on a placebo-adjusted basis. Responder analyses of 24-hour cough frequency reduction at 30%, 50%, and 75% thresholds were statistically significant for patients on Haduvio across all doses. Patients on Haduvio experienced a statistically-significant improvement in the patient-reported Leicester Cough Questionnaire at Day 21. There were no significant treatment period effects from the crossover design for the primary efficacy analysis of relative change from baseline in 24-hour cough frequency. Discontinuations primarily occurred in the first two weeks of Haduvio dosing and were mostly related to adverse events, typically central nervous system and gastrointestinal in nature.